Parkman Healthcare Partners LLC Has $24.53 Million Stake in Gilead Sciences, Inc. $GILD

Key Points

• Parkman Healthcare Partners LLC has reduced its holdings in Gilead Sciences, Inc. by 41.6%, leaving it with approximately $24.5 million worth of shares.
• Several institutional investors, including Plancorp LLC and NatWest Group plc, have increased their stakes in Gilead Sciences, indicating a diverse range of interest in the company's stock.
• Gilead recently announced a quarterly dividend of $0.79, representing an annual yield of 2.7%, which will be paid to shareholders on September 29th.

Parkman Healthcare Partners LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 41.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 218,950 shares of the biopharmaceutical company's stock after selling 155,875 shares during the period. Gilead Sciences makes up about 2.9% of Parkman Healthcare Partners LLC's portfolio, making the stock its 9th biggest position. Parkman Healthcare Partners LLC's holdings in Gilead Sciences were worth $24,533,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences in the 1st quarter valued at approximately $25,000. Activest Wealth Management lifted its stake in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Gilead Sciences in the 1st quarter valued at approximately $29,000. Colonial Trust Advisors lifted its stake in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its stake in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

GILD has been the subject of several research reports. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. UBS Group increased their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Finally, Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Insider Activity

In other news, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the sale, the director directly owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the sale, the chief financial officer directly owned 160,110 shares in the company, valued at approximately $18,977,838.30. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock valued at $9,371,330. Company insiders own 0.27% of the company's stock.

Gilead Sciences Trading Down 0.1%

GILD traded down $0.12 during midday trading on Tuesday, hitting $115.76. 5,348,701 shares of the company were exchanged, compared to its average volume of 5,678,517. The firm has a market capitalization of $143.64 billion, a P/E ratio of 23.06, a P/E/G ratio of 0.79 and a beta of 0.36. Gilead Sciences, Inc. has a 1-year low of $78.73 and a 1-year high of $121.83. The firm's 50 day moving average price is $113.77 and its 200-day moving average price is $109.99. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.